Gemcitabine-cisplatin plus necitumumab
Onartuzumab plus erlotinib
Docetaxel (DOC) and ramucirumab
The focused issue “Personalized Therapy in Lung Cancer” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Na Zhang, Wen-Zhao Zhong and Yi-Long Wu served as the unpaid Guest Editors for the focused issue.